IMPORTANCE Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA 2 enzyme.
L ipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) has been hypothesized to play a causal role in the development of atherosclerosis and to contribute to plaque instability through pathways related to inflammation. 1 A number of epidemiologic studies have shown that higher circulating levels of Lp-PLA 2 activity or mass are associated with an increased risk of coronary events in primary and stable secondary prevention cohorts. 2 Lp-PLA 2 has been shown to be highly concentrated in unstable and ruptured atherosclerotic plaques. 3 Further, in 2 case-control studies, natural deficiency of Lp-PLA 2 activity due to carriage of the V279F null allele in the Lp-PLA 2 gene was associated with a lower risk of developing coronary heart disease (CHD). 4 Darapladib is a selective Lp-PLA 2 inhibitor that reduces Lp-PLA 2 activity in plasma 5 and in atherosclerotic plaques. 6 In phase 2 testing, darapladib did not modify total coronary atheroma volume when compared with placebo on a background of statin therapy, but it appeared to prevent necrotic core expansion as assessed by intravascular ultrasound virtual histology. 7 In the STABILITY trial (Stabilization of Atheroscle- 8 The current phase 3 trial evaluated the efficacy and safety of darapladib on a background of optimal medical therapy in patients recently hospitalized with acute coronary syndrome (ACS).
Methods
The study design of the the SOLID-TIMI 52 trial (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52; ClinicalTrials.gov NCT 01000727) has been previously described. 9 The design was a double-blind, placebocontrolled phase 3 trial that was conducted at 868 sites in 36 countries (eAppendix in Supplement 1). The protocol (Supplement 2) was approved by the relevant institutional review boards or ethics committees and all participants gave written informed consent.
Study Population
Patients were considered eligible for enrollment if they had been hospitalized with an ACS event in the 30 days prior to randomization (unstable angina, non-ST-elevation MI, and ST-elevation MI; Figure 1 and eAppendix 2 in Supplement 1). cotherapy, or polyvascular disease (including carotid or peripheral arterial disease). For patients in whom a percutaneous coronary intervention (PCI) was planned, the procedure was to be completed prior to randomization whenever possible.
Relevant exclusion criteria included planned or completed coronary artery bypass graft (CABG) surgery for the qualifying event (due to an anticipated low event rate during follow-up), current liver disease, severe renal impairment (eGFR<30 mL/min/1.73 m 2 ), New York Heart Association class III or IV heart failure, poorly controlled hypertension or asthma, a history of severe allergic reaction or anaphylaxis, and life expectancy of less than 2 years due to a condition other than cardiovascular disease. Exclusions on the basis of poorly controlled hypertension or asthma or severe allergic reactions were based on theoretical concerns of the study drug that were not confirmed in clinical testing.
Study Procedures
After providing informed consent, participants were assigned using a permuted block randomization without stratification through a telephone-based interactive voice response system to once-daily enteric-coated darapladib 160 mg orally or matching placebo to be swallowed whole and taken with food. Since the efficacy of darapladib could vary by ethnicity and race, this information was selfreported by study participants at randomization according to prespecified categories and captured in the electronic case-report form. After randomization, patients were to be seen at clinic visits for routine clinical and laboratory assessments at months 1, 3, 6, and every 6 months thereafter. Beginning at month 9, telephone visits were also conducted every 6 months between clinic visits. The use of guideline-recommended therapies for patients after an ACS event was strongly recommended throughout the course of the trial. Biannual performance reports were provided to investigators that summarized adherence to standard of care therapies and treatment goals.
End Points
In December 2013, the SOLID-TIMI 52 executive committee reviewed data from the recently completed STABILITY trial prior to the unblinding or closure of the SOLID-TIMI 52 database. 8 Observations from the STABILTY trial suggested that darapladib may modify the incidence of major and total coronary events, but not the incidence of noncoronary vascular events including stroke.
On the basis of these external results that potentially informed upon the efficacy of darapladib, the executive committee voted to revise the statistical analysis plan for the SOLID-TIMI 52 trial to amend the primary end point. This decision was made without communication from the independent data monitoring committee to the executive committee and while all members remained blinded to the SOLID-TIMI 52 results; the independent data monitoring committee was subsequently informed of the decision. The prior secondary end point of major coronary events (CHD death, MI, or urgent coronary revascularization for myocardial ischemia) became the primary end point of the trial. In turn, the composite of cardiovascular death, MI, or stroke became a secondary end point. The number of reported primary end point events was relatively comparable under both definitions and therefore the end point change did not substantially affect the power to evaluate the primary hypothesis. The study protocol was amended to reflect these changes. All interim analyses were conducted prior to the amendment. The sponsor informed the US Food and Drug Administration, the European Medicines Agency, and the Japanese Pharmaceuticals and Medical Devices Agency of the change.
An independent and blinded clinical events committee adjudicated all reported deaths (including deaths reported through vital status searches), cardiac ischemic events (including urgent coronary revascularization for myocardial ischemia), cerebrovascular events, hospitalizations for heart failure, and gastrointestinal neoplasms and polyps. Cardiovascular end point definitions are provided in eAppendix 3 in Supplement 1. All deaths that were unwitnessed were assumed to be cardiovascular in etiology unless a noncardiovascular cause could be determined. As prespecified, coronary revascularization events that were planned prior to randomization but occurred postrandomization were excluded from the coronary revascularization end point definition.
Statistical Analysis
The primary efficacy analysis was conducted in the intentionto-treat population and included all randomized participants. Patients who were event free and who subsequently withdrew consent or were lost to follow-up were censored for the primary end point on the date that primary end point events were last assessed. Complete details are provided in the Reporting and Analysis Plan in Supplement 2. Safety analyses were conducted among patients who received at least 1 dose of study drug. Cox proportional hazards regression models were used to assess the effect of darapladib on the primary end point and additional time-to-event outcomes. For the ontreatment analysis, patients who took the study drug and did not experience an end point event were censored 1 day following the last dose of the study drug. A prespecified landmark analysis examined the rates of the primary end point from randomization to 12 months and beyond 12 months of followup. Patients with a primary end point event prior to 12 months were excluded from the post 12-month analysis. A generalized estimating equations model with repeated measures was used to assess the change in blood pressure over time with covariates that included treatment group, study visit, baseline value, treatment group by visit, and baseline value by visit interactions.
When the study was initially designed, it was determined that 1500 events would be required to yield 90% power to detect a 15.5% reduction in the risk of the primary end point (HR = 0.845) for participants treated with darapladib compared with placebo. On the basis of 2 planned interim analyses, the primary end point was assessed at a threshold of significance of P value less than .049 after applying a flexible α-spending function. At the time of study design, the median duration of follow-up was anticipated to be approximately 3 years. Cumulative event rates were calculated using the Kaplan-Meier method at 3 years. All CIs were 2-sided with a 95% confidence level. Tests for subgroup interaction were considered exploratory and assessed at a prespecified nominal P value of less than .10. All reported P values were 2-sided. Statistical analyses were conducted at the TIMI Study Group and sponsor using SAS statistical software, version 9.
Results
From December 7, 2009, until October 28, 2011, a total of 13 026 participants were randomized into the SOLID-TIMI 52 trial at 868 centers in 36 countries. The longest duration of follow-up was 3.8 years with a median follow-up of 2.5 years (interquartile range [IQR], 2.1-2.8 years). There were 31 167 total patient-years of follow-up.
The final disposition of all study participants is summarized in Figure 1 . Vital status after July 1, 2013, was ascertained in 99.6% of all randomized participants. At study conclusion, there were 13 participants who were lost to follow-up without known vital status. Vital status was ascertained for an additional 71 patients who were classified as lost prior to the close out period; of these patients, 10 had died. During the course of the study, 220 patients withdrew consent (0.7 per 100 person-years) of whom vital status at the end of the trial was obtained in 186 using publically available records (wherever permitted by local law). The numbers of patients who were lost to follow-up or who withdrew consent was similar between treatment groups ( Figure 1 ).
Baseline characteristics were well balanced between treatment groups ( Table 1) . The median age of the study population was 64 years and 74.5% of patients were men. The qualifying ACS event was ST-elevation MI in 45.2%, non-ST-elevation MI in 42.7%, and unstable angina in 12.2% of participants. In the course of treatment for the index event, 86.0% underwent cardiac catheterization and 76.7% underwent PCI prior to randomization. The median time between the date of hospitalization for the qualifying event and randomization was 14 days. At the baseline visit, 94.6% of patients were receiving a statin and 46.1% were recorded to have been taking a statin for at least 8 weeks prior to randomization. The median low-density lipoprotein (LDL) cholesterol concentration was 74.9 mg/dL (interquartile range [IQR], 57.1-96.9 mg/dL). The use of other evidence-based therapies for patients after ACS was comparably high (>85% for each type of medication, including high proportions of patients using aspirin, a β-blocker, and a P2Y 12 inhibitor at randomization), and well-balanced between treatment groups (Table 1) .
Efficacy
At the end of follow-up, the primary end point of major coronary events (CHD death, MI, or urgent coronary revascularization for myocardial ischemia) had occurred in 903 of 6504 participants in the darapladib group and 910 of 6522 participants in the placebo group (16.3% vs 15.6% at 3 years; HR, 1.00 [95% CI, 0.91-1.09]; P = .93; Figure 2 , Table 2 ). The secondary end point of cardiovascular death, MI, or stroke occurred in 824 darapladib-assigned participants and 838 placebo-treated patients (15.0% vs 15.0% at 3 years; HR, 0.99 [95% CI, 0.90-1.09]; P = .78; eFigure 1 in Supplement 1). There were no statistically significant differences between treatment groups in the incidence and number of events for the individual components of the primary end point or additional secondary end points ( Table 2 ). The risk of all-cause mortality was similar between the treatment groups and occurred in 371 patients in the darapladib group and 395 patients in the placebo group (7.3% vs 7.1% at 3 years; HR, 0.94 [95% CI, 0.82-1.08]; P = .40). Additional efficacy end points are reported in Table 2 . The number of MI events by treatment group, according to the Universal Classification of MI, 10 is shown in the eTable in Supplement 1.
Subgroups
At a prespecified threshold of P value less than .10, there was no evidence of heterogeneity across the majority of prespecified subgroups including age, region, renal dysfunction, and other comorbid conditions for the primary end point (Figure 3 ). An interaction of nominal significance was observed on the basis of sex (P value for interaction = .04) and race (P value for interaction = .07). No gradient of efficacy for darapladib vs placebo was observed for patients with higher baseline LDL cholesterol concentrations (P value for interaction = .17) or higher baseline Lp-PLA 2 activity (P value for interaction = .98). The treatment interaction on the basis of sex was no longer significant when the secondary end point of cardiovascular death, MI, or stroke was examined (P value for interaction = .29; eFigure 2 in Supplement 1).
Safety
The incidence of any serious adverse event was similar between treatment groups ( Table 3) . Any adverse event leading to drug discontinuation was 17% in the darapladib group and 12% in the placebo group. Consistent with prior studies, patients treated with darapladib were more likely to report an odor-related concern than those in the placebo group (predominantly odor of the feces, urine, and skin; 11.5% vs 2.5%) and diarrhea (10.6% vs 5.6%) and these concerns contributed to a higher rate of study drug discontinuation in the darapladib group. The incidence of malignancy was similar for patients randomized to darapladib or placebo ( Table 3 ). The change in blood pressure was similar between treatment groups with a trend toward a smaller increase in systolic blood pressure over time for patients taking darapladib compared with those in the placebo group (adjusted mean difference between treatment groups, −0.8 mmHg [95% CI, −1.4 to −0.2]; P = .01). Darapladib did not have a significant effect over time on LDL cholesterol (P = .98), HDL cholesterol (P = .25), or triglycerides (P = .97), as compared with placebo.
Sensitivity Analyses
As a sensitivity analysis, an ontreatment analysis was conducted; darapladib did not reduce the risk of major coronary events (CHD death, MI, or urgent coronary revascularization for myocardial ischemia) for patients while taking the study drug (HR, 0.98 [95% CI, 0.89-1.08]; P = .67). Since early events after ACS may not have been modifiable with an antiinflammatory therapeutic, a prespecified landmark analysis was conducted. Darapladib did not reduce the incidence of major coronary events from the time of randomization to 12 months (HR, 1.04 [95% CI, 0.92- 
Discussion
In patients who were stabilized after an ACS event, darapladib did not reduce the risk of recurrent major coronary events through a median of 2.5 years of follow-up when added to existing guideline-recommended therapies. Fur- ther, darapladib did not reduce the risk of any cardiovascular end point, including any of the individual components of the primary end point. These results were consistent across key subgroups including those stratified by baseline LDL cholesterol concentration and baseline Lp-PLA 2 activity level. Our findings therefore do not support a strategy of targeted Lp-PLA 2 inhibition with darapladib in patients stabilized after an ACS event who are similar to those enrolled into this trial. Prior to the current study, there was evidence to support the theory that inhibition of the Lp-PLA 2 enzyme would translate into clinical benefit. LpPLA 2 is known to hydrolyze oxidized LDL particles leading to the production of byproducts that have been shown through in vitro experiments to exert proinflammatory and proapoptotic effects. [11] [12] [13] Lp-PLA 2 has been identified in unstable and ruptured plaques 3 and is strongly expressed in macrophages in lesions prone to rupture. 14 Further, direct inhibition of Lp-PLA 2 activity has been shown to inhibit progression to advanced coronary atherosclerotic lesions in diabetic and hypercholesterolemic swine. 15 In phase 2 testing, darapladib appeared to stabilize the necrotic core size in coronary atherosclerotic plaques as com- Despite the aforementioned preclinical and observational data that suggested that Lp-PLA 2 may contribute to the progression of atherosclerosis, the current study of more than 13 000 patients with ACS demonstrated no clinical efficacy for the Lp-PLA 2 inhibitor darapladib. Therefore, a key question is whether these findings definitively inform upon the role that Lp-PLA 2 may play in atherogenesis.
In the STABILITY trial, darapladib also did not achieve a reduction in the primary end point of cardiovascular death, MI, or stroke (HR, 0.94 [95% CI, 0.85-1.03]; P = .20), yet directionally favorable signals were observed to suggest that darapladib may reduce the risk of coronary events in patients with stable CHD. Specifically, in the STABILITY trial, darapladib reduced the risk of major coronary events (HR, 0.90 [95% CI, 0.82-1.00]; P = .045) and total coronary events (HR, 0.91 [95% CI, 0.84-0.98]; P = .02). 8 Although a nominal reduction in these 2 secondary end points could only be considered exploratory, the findings appeared biologically plausible. However, these observations were not confirmed in the current study. Moreover, a signal of efficacy was not observed when a landmark analysis was conducted to evaluate the drug's efficacy once patients were stabilized for 12 months beyond their ACS event. Nonetheless, it remains possible that differences in the study populations and the duration of follow-up between the 2 phase 3 trials of darapladib may have contributed to the lack of apparent benefit in the current clinical trial. Prior studies have demonstrated that Lp-PLA 2 mass and activity are not prognostic when assessed early after hospitalization with ACS, 16, 17 but are associated with an increased risk of cardiovascular events in patients with stable CHD. 16, [18] [19] [20] Supporting these prior observations, baseline Lp-PLA 2 activity levels were not associated with a treatment benefit with darapladib in the current study; although tests for subgroup interactions were relatively underpowered. However, 2 large clinical trials of darapladib have now failed to significantly reduce the risk of future cardiovascular events. Although these results do not support a role for Lp-PLA 2 as a direct therapeutic target, it may be challenging to demonstrate incremental benefit for an Lp-PLA 2 inhibitor beyond existing therapies for the management of ACS. In particular, in addition to their favorable effects on lipid parameters, statins reduce Lp-PLA 2 activity and mass to an extent that cannot be predicted based on the change in LDL concentration alone. 15 In addition, although unlikely, the possibility that Lp-PLA 2 remains an important target cannot be excluded, but variable plaque penetration of the drug or unidentified off-target effects of darapladib could be responsible for the absence of efficacy in the current study.
Although the current trial did not demonstrate clinical efficacy for darapladib, there are limitations that can be considered. The study design did not screen patients on the basis of their Lp-PLA 2 activity levels; therefore, this study cannot exclude the possibility that patients with higher baseline levels of Lp-PLA 2 activity would benefit from treatment. However, a gradient of efficacy was not observed when groups were stratified on the basis of Lp-PLA 2 activity. The study also did not target a specific degree of Lp-PLA 2 inhibition; however, the 160-mg dose of darapladib is anticipated to achieve an approximate 66% reduction in Lp-PLA 2 activity on a background of statin therapy. In addition, many cardiovascular events occurring early after ACS may relate more to thrombotic mechanisms and may not be modifiable through Lp-PLA 2 inhibition, which could have limited the ability of this study to detect a difference. However, clinical efficacy was not observed through 2.5 years of follow-up.
Overall, these results highlight some of the challenges that may occur during the development of novel therapeutics that are directed toward the inflammatory cascade. In particular, 
